June 3, 2022
A Japanese health ministry panel on June 2 backed the approval of seven drugs including two new molecular entities (NMEs), with Sanofi’s anti-C1s monoclonal antibody sutimlimab among them. The medicines, reviewed by the Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC)...read more